Author(s) Daniel S. Schwartz, MD, MBA
Medical Director of Thoracic Oncology, St Catherine of Siena Medical Center, Catholic Health Services, Smithtown, New York
Disclosure: Daniel S. Schwartz, MD, MBA, has disclosed no relevant financial relationships.
Read more here:
Fast Five Quiz: Genetics of Non-Small Cell Lung Cancer - Medscape
The report on the Human Genetics Market is a compilation of intelligent, broad research studies that will help players and stakeholders to make informed business decisions in future. It offers specific and reliable recommendations for players to better tackle challenges in the Human Genetics market. Furthermore, it comes out as a powerful resource providing up to date and verified information and data on various aspects of the Human Genetics market. Readers will be able to gain deeper understanding of the competitive landscape and its future scenarios, crucial dynamics, and leading segments of the Human Genetics market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the Human Genetics market.
The Global Human Genetics Market is growing at a faster pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2019 to 2026.
Human Genetics Market: A Competitive Perspective
Competition is a major subject in any market research analysis. With the help of the competitive analysis provided in the report, players can easily study key strategies adopted by leading players of the Human Genetics market. They will also be able to plan counterstrategies to gain a competitive advantage in the Human Genetics market. Major as well as emerging players of the Human Genetics market are closely studied taking into consideration their market share, production, revenue, sales growth, gross margin, product portfolio, and other significant factors. This will help players to become familiar with the moves of their toughest competitors in the Human Genetics market.
Human Genetics Market: Drivers and Limitations
The report section explains the various drivers and controls that have shaped the global market. The detailed analysis of many market drivers enables readers to get a clear overview of the market, including the market environment, government policy, product innovation, development and market risks.
The research report also identifies the creative opportunities, challenges, and challenges of the Human Genetics market. The framework of the information will help the reader identify and plan strategies for the potential. Our obstacles, challenges and market challenges also help readers understand how the company can prevent this.
Human Genetics Market: Segment Analysis
The segmental analysis section of the report includes a thorough research study on key type and application segments of the Human Genetics market. All of the segments considered for the study are analyzed in quite some detail on the basis of market share, growth rate, recent developments, technology, and other critical factors. The segmental analysis provided in the report will help players to identify high-growth segments of the Human Genetics market and clearly understand their growth journey.
Ask for Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=177432&utm_source=NT&utm_medium=888
Human Genetics Market: Regional Analysis
This section of the report contains detailed information on the market in different regions. Each region offers a different market size because each state has different government policies and other factors. The regions included in the report are North America, Europe, Asia Pacific, the Middle East and Africa. Information about the different regions helps the reader to better understand the global market.
Table of Content
1 Introduction of Human Genetics Market
1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions
2 Executive Summary
3 Research Methodology of Market Research Intellect
3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources
4 Human Genetics Market Outlook
4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis
5 Human Genetics Market , By Deployment Model
5.1 Overview
6 Human Genetics Market , By Solution
6.1 Overview
7 Human Genetics Market , By Vertical
7.1 Overview
8 Human Genetics Market , By Geography
8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East
9 Human Genetics Market Competitive Landscape
9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies
10 Company Profiles
10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments
11 Appendix
11.1 Related Research
Request Report Customization @ https://www.marketresearchintellect.com/product/global-human-genetics-market-size-forecast/?utm_source=NT&utm_medium=888
About Us:
Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.
Contact Us:
Mr. Steven FernandesMarket Research IntellectNew Jersey ( USA )Tel: +1-650-781-4080
Email: [emailprotected]
TAGS: Human Genetics Market Size, Human Genetics Market Growth, Human Genetics Market Forecast, Human Genetics Market Analysis, Human Genetics Market Trends, Human Genetics Market
Read more here:
Human Genetics Market Increasing Demand with Leading Player, Comprehensive Analysis, Forecast to 2026 - News Times
Michigan State University received $700,000 from the U.S. Department of Agricultures National Institute of Food and Agriculture to invest in itspotato breeding and genetics program.
The award is part of a $2.25 million four-part grant to support potato breeding in strategic areas across the country, which includes partnering institutions University of Minnesota, North Dakota State University and the University of Wisconsin.
Potato production in Michigan, Minnesota, North Dakota and Wisconsin accounts for nearly a quarter of U.S. potato acreage and a farmgate value of $982.5 million. The North Central region which also includes Illinois, Indiana, Iowa, Kansas, Missouri, Nebraska, Ohio and South Dakota is responsible for the most potato production outside of the Pacific Northwest.
Dave Douches, a professor in theMSU Department of Plant, Soil and Microbial Sciences, has led the MSU potato breeding and genetics program for nearly 30 years. The program has produced nearly 30 new potato varieties. The most recent, Blackberry, is apurple-fleshed varietythat took more than 20 years to develop. It is resistant to potato scab and has high antioxidant levels.
This is a new round of funding for our long-term genetics work to help us interact with growers and develop new varieties, Douches said. The USDA has supported these efforts with multiple grants. The advancements weve made wouldnt be possible without this support.
The grant proposal outlines the following objectives:
Douches said that geneticists are looking not only to improve varieties for growers by focusing on disease and pest resistance, but also to meet consumer demand. Enhanced nutritional profiles are a crucial aspect of the research.
Weve been most known for producing potatoes that go into snacks such as potato chips, Douches said. Thats been important to us, but the companies were working with want to explore how we can improve the nutritional properties of our varieties. This can help us make snacking healthier, and all of our partners from growers to companies have shown interest in that.
Source: Michigan State University
Read the rest here:
USDA grant supports potato breeding and genetics program - Potato News Today
Signal Genetics, Inc. (MGEN) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on March 11. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of +24.2%.
Revenues are expected to be $0.97 million, up 102.1% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Signal Genetics, Inc.
For Signal Genetics, Inc.The Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.
Story continues
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Signal Genetics, Inc. Will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Signal Genetics, Inc. Would post a loss of $0.30 per share when it actually produced a loss of $0.36, delivering a surprise of -20%.
Over the last four quarters, the company has beaten consensus EPS estimates just once.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Signal Genetics, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportSignal Genetics, Inc. (MGEN) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research
Seattle Genetics, Inc. (Nasdaq:SGEN) announced today the cancellation of the Companys presentation and webcast at the Cowen 40th Annual Healthcare Conference on Tuesday, previously scheduled to take place on March 3, 2020 at 9:20 a.m. Eastern Time. Management will no longer be attending the conference as a precautionary measure related to travel amidst the evolving coronavirus situation.
About Seattle Genetics
Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative medicines targeting cancer to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) use the companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. In addition, investigational agent tucatinib, a small molecule tyrosine kinase inhibitor, is in late-stage development for HER2-positive metastatic breast cancer and in clinical development for metastatic colorectal cancer. The company is headquartered in Bothell, Washington, and has offices in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200302005307/en/
Contacts
Investors:Peggy Pinkston(425) 527-4160ppinkston@seagen.com
Media:Monique Greer(425) 527-4641mgreer@seagen.com
Original post:
Seattle Genetics Announces Cancellation of Presentation and Webcast at the Cowen 40th Annual Healthcare Conference - Yahoo Finance
Myriad Genetics, Inc. (MYGN) is priced at $16.72 after the most recent trading session. At the very opening of the session, the stock price was $18.01 and reached a high price of $18.67, prior to closing the session it reached the value of $18.06. The stock touched a low price of $16.68.
Myriad Genetics, Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the companys stock is recorded $48.40 on 08/02/19, with the lowest value was $16.66 for the same time period, recorded on 02/28/20.
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stocks existing status and the future performance. Presently, Myriad Genetics, Inc. shares are logging -65.45% during the 52-week period from high price, and 0.36% higher than the lowest price point for the same timeframe. The stocks price range for the 52-week period managed to maintain the performance between $16.66 and $48.40.
The companys shares, operating in the sector of services managed to top a trading volume set approximately around 1.67 million for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Myriad Genetics, Inc. (MYGN) recorded performance in the market was -38.60%, having the revenues showcasing -35.04% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 1.24B, as it employees total of 2600 workers.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 26.23, with a change in the price was noted -11.58. In a similar fashion, Myriad Genetics, Inc. posted a movement of -40.92% for the period of last 100 days, recording 1,050,314 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the companys financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders equity. The total Debt to Equity ratio for MYGN is recording 0.21 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.21.
Raw Stochastic average of Myriad Genetics, Inc. in the period of last 50 days is set at 0.45%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 0.45%. In the last 20 days, the companys Stochastic %K was 5.99% and its Stochastic %D was recorded 5.32%.
Bearing in mind the latest performance of Myriad Genetics, Inc., several moving trends are noted. Year-to-date Price performance of the companys stock appears to be encouraging, given the fact the metric is recording -38.60%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -28.94%, alongside a downfall of -45.05% for the period of the last 12 months. The shares increased approximately by 17.44% in the 7-day charts and went up by -7.06% in the period of the last 30 days. Common stock shares were lifted by -35.04% during last recorded quarter.
Continue reading here:
Time to Buy Beat-Down Myriad Genetics, Inc. (MYGN) Stock? Here is the INSIGHT - The InvestChronicle
How high altitudes affect peoples breathing and its coordination with the heart beat is due to genetic differences, say researchers.
Clear physiological differences have already been demonstrated between people living in the Himalayas and Andes compared with people living at sea level, revealing an evolutionary adaptation in the control of blood flow and oxygen delivery to the brain and the rest of the body.
Now an international team led by Aneta Stefanovska, PhD, a professor at Lancaster University has identified genes that are related to cardiorespiratory function during so-called acute periodic breathing. Their report is published in the Journal of Physiology.
Periodic breathing (PB) occurs in most humans at high altitudes and is characterized by periodic alternations between hyperventilation (too-fast breathing) and apnea (no breathing). The altered respiratory pattern due to periodic breathing is accompanied by changes in heart rate and blood flow.
Breathing, ECG of the heart, and microvascular blood flow were simultaneously monitored for 30 minutes in 22 healthy male subjects, with the same measurements repeated under normal and low oxygen levels, both at real and simulated altitudes of up to 3800m.
As part of the experiment, the participants were also taken in a cable car to a high altitude laboratory at the top of Aiguille du Midi mountain in Chamonix in France and tested immediately on arrival and after six hours at this altitude of 3842m.
The researchers found that orchestration between the participants hearts and lungs, as measured by phase coherence, responded differently to periodic breathing depending on whether they had one of two specific genetic variants affecting the cardiorespiratory response to insufficient oxygen.
Chronic periodic breathing is generally seen as an unfavorable state, being associated with increased mortality in chronic heart failure, but in healthy people it may be an indication of better alertness to oxygen insufficiency at high altitudes.
Hypoxia, as well occurring during rapid ascents to high-altitudes, can also be a significant problem at sea-level, being a contributory factor in many health conditions including cancer, strokes, and heart attacks.
Stefanovska says in a release, The similarities between hypoxia-induced PB at altitude, and the breathing characteristics observed in certain pathological states, provide an opportunity to further our understanding of the physiological processes involved in chronic hypoxic states that occur even when oxygen is abundant.
Considering living systems as collections of interacting oscillators whose dynamics is governed by multiple underlying open systems enables the observation of functional changes over time, and investigation of how they are altered in health and disease.
Image: Participants were also taken in a cable car to a high altitude laboratory at the top of Aiguille du Midi mountain in Chamonix in France. Credit: Lancaster University
See the original post:
How Cardiorespiratory Function Is Related to Genetics - Sleep Review
Signal Genetics, Inc. (MGEN - Free Report) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2019. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on March 11. On the other hand, if they miss, the stock may move lower.
While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.
Zacks Consensus Estimate
This company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents a year-over-year change of +24.2%.
Revenues are expected to be $0.97 million, up 102.1% from the year-ago quarter.
Estimate Revisions Trend
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.
Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.
Price, Consensus and EPS Surprise
Earnings Whisper
Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).
The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.
Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.
A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.
Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).
How Have the Numbers Shaped Up for Signal Genetics, Inc.
For Signal Genetics, Inc.The Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.
On the other hand, the stock currently carries a Zacks Rank of #3.
So, this combination makes it difficult to conclusively predict that Signal Genetics, Inc. Will beat the consensus EPS estimate.
Does Earnings Surprise History Hold Any Clue?
While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.
For the last reported quarter, it was expected that Signal Genetics, Inc. Would post a loss of $0.30 per share when it actually produced a loss of $0.36, delivering a surprise of -20%.
Over the last four quarters, the company has beaten consensus EPS estimates just once.
Bottom Line
An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.
That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.
Signal Genetics, Inc. Doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.
See original here:
Signal Genetics, Inc. (MGEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release - Zacks.com
Amazing-modern-genetics
Will the 2020 crop season shape up like last year? It would be quite a stretch to think the elements could stoop to that level a second year in a row.
Ive been in the industry 35 years and my dad is 86, says John Kermicle, Brand Manager for AgriGold. He kept comparing last year to other years and finally said, John, there hasnt been any other year like 2019. So, it was the worst.
Kermicle was in Texas last week at the companys Commodity Classic trade show booth. He told HAT the advances in seed and seed treatments continue to benefit farmers in good conditions and bad.
In general, corn yields were pretty good again, he said. Some areas were off, but truly todays genetics with the treatments that we have today, its not like the 1980s or early 2000s. They can handle an amazing amount of weather and still do pretty well.
In presentations at the AgriGold booth, Kermicle touted their customers success in the most recent corn yield contest. The contest, he says, is another important tool for corn growers.
We want to help growers grow more corn. Thats why were in business. So, the contest really helps growers think outside the box, and then how can we take these learnings and apply it across whole farm operations? Thats kind of our approach.
He says there are several new products in the 2020 lineup.
We have a really strong research program and the first time we see some of our products are as conventionals. Were introducing eight new conventionals that will then have traits a year of two after that.
Learn more at http://agrigold.com/.
Read more from the original source:
When Tough Weather Hits Crops, Modern Genetics Helps Them Perform - Hoosier Ag Today
BETHESDA, Md., March 4, 2020 /PRNewswire/ --Sarah H. Elsea, PhD, FACMG, professor of molecular and human genetics at Baylor College of Medicine and senior director of biochemical genetics at Baylor Genetics, has been elected to the board of directors of the ACMG Foundation for Genetic and Genomic Medicine.The ACMG Foundationis a national nonprofit foundation dedicated to facilitating the integration of genetics and genomics into medical practice. The board members are active participants, serving as advocates for the Foundation and for advancing its policies and programs. Dr. Elsea was elected to a two-year term starting immediately.
"It is our pleasure to welcome Dr. Sarah Elsea to the ACMG Foundation Board of Directors. Dr. Elsea's experience in medical genetics and commitment to the mission of the College will add greatly to our ability to support clinical and educational activities on behalf of our members and the public," said ACMG Foundation President Bruce R. Korf, MD, PhD, FACMG.
Dr. Elsea received a Bachelor of Science in Chemistry with a minor in biology from Missouri State University and a PhD in biochemistry from Vanderbilt University. She completed postdoctoral fellowships in molecular and biochemical genetics at Baylor College of Medicine and is board certified by the American Board of Medical Genetics and Genomics.She held faculty appointments at Michigan State University and the Medical College of Virginia at Virginia Commonwealth University prior to returning to Baylor College of Medicine in 2013. Her research is focused on the discovery, pathomechanisms, diagnosis and treatment of rare and complex disease, particularly neurodevelopmental and metabolic disorders that involve sleep disturbance, behavioral phenotypes, obesity and cancer. While most of the work in Dr. Elsea's lab has a molecular basis, her work with children and families living with Smith-Magenis syndrome and other neurodevelopmental disorders has focused several studies toward the family, sibling and caregiver experience for those caring for and living with individuals with complex neurodevelopmental conditions. Her primary goals have focused toward supporting education and research to develop appropriate interventions to improve the health and quality of life of persons with neurodevelopmental and metabolic disorders using an integrated approach to education, outreach and mentoring. Dr. Elsea works collaboratively with support groups to develop relevant, targeted research to inform and improve upon quality of life for individuals affected by genetic conditions. Dr. Elsea serves on the board of directors of the American Board of Medical Genetics and Genomics and is chair of the Parents and Researchers Interested in Smith-Magenis Syndrome (PRISMS) Professional Advisory Board.
About being elected to the ACMG Foundation Board of Directors, Dr. Elsea said, "As we focus toward defining targeted treatments for both rare and common disease, we have an increasing need to translate genetics in healthcare.The mission of the Foundation to support and foster the training and education of medical geneticists and to enhance community education and awareness of genetics and genomics is at the heart of my work. I am both honored and delighted for the opportunity to support the ACMG Foundation Board of Directors, and I look forward to working with the Foundation to advance these goals."
A complete roster of the ACMG Foundation board can be found at http://www.acmgfoundation.org.
About the ACMG Foundation for Genetic and Genomic Medicine
The ACMG Foundation for Genetic and Genomic Medicine, a 501(c)(3) nonprofit organization, is a community of supporters and contributors who understand the importance of medical genetics and genomics in healthcare. Established in 1992, the ACMG Foundation supports the American College of Medical Genetics and Genomics (ACMG) mission to "translate genes into health." Through its work, the ACMG Foundation fosters charitable giving, promotes training opportunities to attract future medical geneticists and genetic counselors to the field, shares information about medical genetics and genomics, and sponsors important research. To learn more and support the ACMG Foundation mission to create "Better Health through Genetics" visit acmgfoundation.org.
Kathy Moran, MBAkmoran@acmg.net
View original content to download multimedia:http://www.prnewswire.com/news-releases/sarah-elsea-phd-facmg-is-elected-to-the-board-of-directors-of-the-acmg-foundation-for-genetic-and-genomic-medicine-301015856.html
SOURCE American College of Medical Genetics and Genomics
Go here to see the original:
Sarah Elsea, PhD, FACMG Is Elected to the Board of Directors of the ACMG Foundation for Genetic and Genomic Medicine - BioSpace